M. Dittmann

A comparative study of in vitro air-liquid interface culture models of the human airway epithelium evaluating cellular heterogeneity and gene expression at single cell resolution

This study compares gene expression and cellular heterogeneity in HAE cultures derived from BCi-NS1.1 cell lines and primary cells using scRNA-Seq, finding similar morphology and transcriptional patterns but some interferon gene differences.

In-silico docking platform with serine protease inhibitor (SERPIN) structures identifies host cysteine protease targets with significance for SARS-CoV-2

The paper uses in-silico docking to identify SERPIN targets in SARS-CoV-2, finding novel interactions and validating their role in viral replication.

A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8

This study establishes a neonatal mouse model to study SARS-CoV-2 transmissibility, showing variant differences in infectious shedding and identifying ORF8's role in transmission.

Antiviral DExD/H-box helicase 60 selectively inhibits translation from type II internal ribosome entry sites

This study shows that DDX60 selectively inhibits translation from type II viral IRESs, reducing replication of EMCV and FMDV but not type I IRES viruses.

ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection

The paper identifies ACE2-containing exosomes, termed defensosomes, that inhibit SARS-CoV-2 infection by binding and blocking viral entry.

Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocation.

The paper shows that gut microbiome dysbiosis in COVID-19 patients is linked to increased risk of bacteremia and microbial translocation.

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.

This study compares the sensitivity of SARS-CoV-2 and SARS-CoV to type I interferon, finding SARS-CoV-2 is more susceptible to IFN-I treatment.

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19

This study compares the antiviral efficacy of PF-00835231, GC-376, and remdesivir in human airway models, showing PF-00835231 is at least as potent as the others and not affected by P-glycoprotein efflux.

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.

The paper assesses neutralization capacity and antibody titers against SARS-CoV-2 antigens in recovered healthcare workers, finding that high titers of multiple isotypes correlate with neutralization.

The regulatory factor ELF1 triggers a critical wave of transcription in the antiviral response to type I interferon

This paper identifies ELF1 as a non-canonical regulator of antiviral ISG expression, showing it amplifies and prolongs the type I interferon response by inducing a distinct set of antiviral genes.